Innate immunity is a key component in the pathogenesis of oral mucositis, a universal toxicity of chemoradiation therapy (CRT). Dusquetide, a novel Innate Defense Regulator, has demonstrated both nonclinical and clinical efficacy in ameliorating severe oral mucositis (SOM). Long term follow-up studies from the Phase 2 clinical study evaluating dusquetide as a treatment for SOM in head and neck cancer (HNC) patients receiving CRT have now been completed. Extended analysis indicates that dusquetide therapy was well-tolerated and did not contribute to increased infection, tumor growth or mortality. Potential ancillary benefits of duquetide therapy were also identified.
|Number of pages||3|
|State||Published - Sep 2017|
Bibliographical noteFunding Information:
Funding: A portion of this work was supported by the National Institute of Dental and Craniofacial Research Small Business Innovation Research grant # 1R43 DE024032-01(Soligenix, Inc).
© 2017 The Authors
- Cancer supportive care
- Head and neck cancer
- Oral mucositis
ASJC Scopus subject areas
- Applied Microbiology and Biotechnology